An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis [0.03%]
开放性随机对照试验：硫唑嘌呤与霉酚酸酯诱导自身免疫性肝炎初始治疗缓解的比较
Romée J A L M Snijders,Anna E C Stoelinga,Tom J G Gevers et al.
Romée J A L M Snijders et al.
Background & aims: Patients with autoimmune hepatitis (AIH) almost invariably require lifelong immunosuppressive treatment. There is genuine concern about the efficacy and tolerability of the current standard combination ...
Randomized Controlled Trial
Journal of hepatology. 2024 Apr;80(4):576-585. DOI:10.1016/j.jhep.2023.11.032 2024
Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly patients with chronic hepatitis B [0.03%]
替诺福韦酯长期使用增加慢性乙肝老年患者的骨折风险
Terry Cheuk-Fung Yip,Jimmy Che-To Lai,Tsz-Fai Yam et al.
Terry Cheuk-Fung Yip et al.
Background & aims: The use of tenofovir disoproxil fumarate (TDF) is associated with a reduction in bone mineral density and an increase in bone metabolism biomarkers. However, data on clinical bone fractures remain limit...
Normal weight and central obesity as predictors of increased all-cause mortality in metabolic dysfunction associated steatotic liver disease [0.03%]
正常体重和中心性肥胖在代谢功能障碍相关肝脂肪变性疾病中作为全因死亡率升高的预测因素
Junhong Chen,Hao Zhou,Kai Liu
Junhong Chen
Liver disease is a significant risk factor for cardiovascular outcomes - A UK Biobank study [0.03%]
肝病是心血管预后的重要风险因素——英国生物银行研究结果
Chiyu He,Di Lu,Shusen Zheng et al.
Chiyu He et al.
Reply to: "5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial. Was an accurate statistical analysis performed?" [0.03%]
对“5-甲基四氢叶酸可增强普萘洛尔于肝硬化患者中的降低门脉压力效果：一项随机对照试验。统计分析正确吗？”的回答
Ranka Vukotic,Roberto Di Donato,Jaime Bosch et al.
Ranka Vukotic et al.
Randomized Controlled Trial
Journal of hepatology. 2024 Apr;80(4):e162-e163. DOI:10.1016/j.jhep.2023.11.025 2024
Episodic overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt does not increase mortality in patients with cirrhosis [0.03%]
经颈静脉肝内门体分流术后的阵发性显性肝性脑病不增加肝硬化患者的死亡率
Silvia Nardelli,Oliviero Riggio,Fabio Marra et al.
Silvia Nardelli et al.
Background & aims: Overt hepatic encephalopathy (OHE) is a major complication of transjugular intrahepatic portosystemic shunt (TIPS) placement, given its high incidence and possibility of refractoriness to medical treatm...
Observational Study
Journal of hepatology. 2024 Apr;80(4):596-602. DOI:10.1016/j.jhep.2023.11.033 2024
Preventing liver disease with policy measures to tackle alcohol consumption and obesity: The HEPAHEALTH II study [0.03%]
防治酒精摄入和肥胖造成的肝病政策研究：HEPAHEALTH II 研究
Lise Retat,Laura Webber,Peter Jepsen et al.
Lise Retat et al.
Background & aims: Chronic liver disease (CLD) causes 1.8% of all deaths in Europe, many of them from liver cancer. We estimated the impact of several policy interventions in France, the Netherlands, and Romania. ...
Hepatic prohibitin 1 and methionine adenosyltransferase α1 defend against primary and secondary liver cancer metastasis [0.03%]
肝部 prohibitin 1 和腺苷甲硫氨酰转移酶α1防御原发性和继发性肝癌转移
Wei Fan,DuoYao Cao,Bing Yang et al.
Wei Fan et al.
Background & aims: The liver is a common site of cancer metastasis, most commonly from colorectal cancer, and primary liver cancers that have metastasized are associated with poor outcomes. The underlying mechanisms by wh...
Effects of tetrathiomolybdate on copper metabolism in healthy volunteers and in patients with Wilson disease [0.03%]
四硫钼酸盐对健康志愿者和威尔森病患者铜代谢的影响
Frederik Teicher Kirk,Ditte Emilie Munk,Eugene Scott Swenson et al.
Frederik Teicher Kirk et al.
Background & aims: In Wilson disease (WD), copper accumulates in the liver and brain causing disease. Bis-choline tetrathiomolybdate (TTM) is a potent copper chelator that may be associated with a lower risk of inducing p...
Randomized Controlled Trial
Journal of hepatology. 2024 Apr;80(4):586-595. DOI:10.1016/j.jhep.2023.11.023 2024
Combined inhibition of Stat3 and periostin synergistically protects mice against liver fibrosis [0.03%]
STAT3和岩藻糖抑制联合协同保护小鼠免受肝纤维化侵害
Hongjun Xiao,Dan Niu,Bo Zhang
Hongjun Xiao